^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous T-cell Lymphoma |
| Drug: | tenalisib (RP6530) (PI3K inhibitor, PI3Kδ inhibitor, PI3Kγ inhibitor, SIK3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)
Published date:
04/13/2018
Excerpt:
Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Tenalisib (RP6530), the Company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL).
